Novo Nordisk Chief Discusses Risk-Taking and Diversification Beyond Ozempic

Novo Nordisk's chief, Mike Doustdar, emphasized injecting risk-taking into the Ozempic maker, expressing openness to large deals and a strategy to reduce reliance on weight-loss drugs.